ProCE Banner Activity

Newly Approved: T-VEC for Melanoma After Resection

Clinical Thought
I examine the appropriate and effective use of T-VEC for treatment of recurrent melanoma after primary surgical resection in a comorbid, elderly patient.

Released: January 11, 2016

Expiration: January 09, 2017

No longer available for credit.

Share

Faculty

Howard L. Kaufman

Howard L. Kaufman, MD

Associate Director for Clinical Sciences
Chief Surgical Officer

Department of Surgical Oncology
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational donation from

Amgen, Inc.

Faculty Disclosure

Primary Author

Howard L. Kaufman, MD

Associate Director for Clinical Sciences
Chief Surgical Officer

Department of Surgical Oncology
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

Howard L. Kaufman, MD, has disclosed that he has received consulting fees from Alkermes, Amgen, EMD Serono, Merck, Prometheus, and sanofi-aventis; has received funds for research support from Amgen; and has served on a speaker bureau for Merck.